nCage’s CEO John Bason is presenting at Prague Bio
nCage Therapeutics and Ryvu have agreed to a Research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform. nCage has developed a TRAP cage platform where the protein cages are synthetic virus-like particles (VLPs), that can be used to display biological material on their surface or transport molecules such as nucleic acids or proteins into the interior of a target cell. This collaboration is focusing on the latter where the TRAP cage can be utilised as a novel drug delivery system (DDS) that could improve the efficacy and safety of current ADCs.
Please find below is our press release.